The investigational study medication, AR1001, consists of 2 pills that you take each morning before breakfast. It is designed to help brain cells grow, repair themselves, and communicate. This may slow or reverse early signs of Alzheimer’s disease and mild cognitive impairment progression.
The study drug has been tested in humans and appears to be well tolerated. However, it is not an approved early Alzheimer’s treatment. Therefore, it is considered investigational and can only be used in research.
Investigational means the study medication is not approved by regulatory authorities like the US Food and Drug Administration (FDA), and it can only be used in clinical research studies like POLARIS-AD.